Anticoagulation Risk Tools
CHA₂DS₂‑VASc & HAS‑BLED scores for stroke/bleeding risk assessment
ESC 2024 Guidelines [citation:1]
CHA₂DS₂‑VASc Risk Factors
1 pts
1 pts
2 pts
1 pts
2 pts
1 pts
1 pts
1 pts
Quick Reference
CHA₂DS₂‑VASc
0: Low risk (no OAC)
1: Moderate (consider OAC)
≥2 (men) / ≥3 (women): OAC indicated [citation:4][citation:9]
HAS‑BLED
≤2: Low bleeding risk
≥3: High bleeding risk – frequent monitoring [citation:1][citation:8]
DOAC Preference [citation:6]
In older adults, apixaban and dabigatran preferred over rivaroxaban and warfarin due to lower bleeding risk.
2023 Beers Criteria: caution with rivaroxaban and warfarin in elderly [citation:6]
Monitoring
- • CBC, renal/liver function annually
- • TTR target >65% for warfarin [citation:9]
- • Reassess at every visit [citation:1]